File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Vaginal misoprostol as medical treatment for first trimester spontaneous miscarriage

TitleVaginal misoprostol as medical treatment for first trimester spontaneous miscarriage
Authors
KeywordsExpectant management
Miscarriage
Misoprostol
Randomized trial
Spontaneous
Issue Date2001
PublisherOxford University Press. The Journal's web site is located at http://humrep.oxfordjournals.org/
Citation
Human Reproduction, 2001, v. 16 n. 7, p. 1493-1496 How to Cite?
AbstractBackground: Misoprostol is effective for cervical priming prior to suction evacuation in first trimester pregnancy termination. This is the first randomized study to compare vaginal misoprostol versus expectant treatment in women presenting with spontaneous miscarriage. Methods: Sixty women presenting with spontaneous miscarriage were recruited to the study at the Queen Mary Hospital between 1998 and 1999. They were randomized to group 1: misoprostol; and group 2: expectant management. Women in the misoprostol group received vaginal misoprostol 400 μg on days 1, 3 and 5. The expectant group was followed up according to the same schedule. Suction evacuation was performed if there was excessive bleeding or abdominal pain; or if a gestational sac was detected by transvaginal scan on day 15. Results: Fifty-nine women completed the trial. Those who did not require suction evacuation up to the time of return of normal menstruation were considered to be successful. The incidence of side-effects was comparable between the two groups. Three women in the expectant group and one in the misoprostol group underwent emergency suction evacuation because of excessive bleeding. The mean duration of vaginal bleeding was similar for both groups (14.6 days in the misoprostol group versus 15.0 days in the expectant group). The successful rate in the misoprostol group was significantly higher than that of the expectant group (83.3 versus 48.3%, P < 0.05). Conclusion: We recommend repeated vaginal misoprostol 400 μg given on days 1, 3 and 5 as a treatment option for women with first trimester spontaneous miscarriage.
Persistent Identifierhttp://hdl.handle.net/10722/87248
ISSN
2015 Impact Factor: 4.621
2015 SCImago Journal Rankings: 2.271
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorNgai, SWen_HK
dc.contributor.authorChan, YMen_HK
dc.contributor.authorTang, OSen_HK
dc.contributor.authorHo, PCen_HK
dc.date.accessioned2010-09-06T09:27:14Z-
dc.date.available2010-09-06T09:27:14Z-
dc.date.issued2001en_HK
dc.identifier.citationHuman Reproduction, 2001, v. 16 n. 7, p. 1493-1496en_HK
dc.identifier.issn0268-1161en_HK
dc.identifier.urihttp://hdl.handle.net/10722/87248-
dc.description.abstractBackground: Misoprostol is effective for cervical priming prior to suction evacuation in first trimester pregnancy termination. This is the first randomized study to compare vaginal misoprostol versus expectant treatment in women presenting with spontaneous miscarriage. Methods: Sixty women presenting with spontaneous miscarriage were recruited to the study at the Queen Mary Hospital between 1998 and 1999. They were randomized to group 1: misoprostol; and group 2: expectant management. Women in the misoprostol group received vaginal misoprostol 400 μg on days 1, 3 and 5. The expectant group was followed up according to the same schedule. Suction evacuation was performed if there was excessive bleeding or abdominal pain; or if a gestational sac was detected by transvaginal scan on day 15. Results: Fifty-nine women completed the trial. Those who did not require suction evacuation up to the time of return of normal menstruation were considered to be successful. The incidence of side-effects was comparable between the two groups. Three women in the expectant group and one in the misoprostol group underwent emergency suction evacuation because of excessive bleeding. The mean duration of vaginal bleeding was similar for both groups (14.6 days in the misoprostol group versus 15.0 days in the expectant group). The successful rate in the misoprostol group was significantly higher than that of the expectant group (83.3 versus 48.3%, P < 0.05). Conclusion: We recommend repeated vaginal misoprostol 400 μg given on days 1, 3 and 5 as a treatment option for women with first trimester spontaneous miscarriage.en_HK
dc.languageengen_HK
dc.publisherOxford University Press. The Journal's web site is located at http://humrep.oxfordjournals.org/en_HK
dc.relation.ispartofHuman Reproductionen_HK
dc.rightsHuman Reproduction. Copyright © Oxford University Press.en_HK
dc.subjectExpectant managementen_HK
dc.subjectMiscarriageen_HK
dc.subjectMisoprostolen_HK
dc.subjectRandomized trialen_HK
dc.subjectSpontaneousen_HK
dc.titleVaginal misoprostol as medical treatment for first trimester spontaneous miscarriageen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0268-1161&volume=16&issue=7&spage=1493&epage=1496&date=2001&atitle=Vaginal+misoprostol+as+medical+treatment+for+first+trimester+spontaneous+miscarriageen_HK
dc.identifier.emailHo, PC:pcho@hku.hken_HK
dc.identifier.authorityHo, PC=rp00325en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.pmid11425836-
dc.identifier.scopuseid_2-s2.0-0034942963en_HK
dc.identifier.hkuros61643en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0034942963&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume16en_HK
dc.identifier.issue7en_HK
dc.identifier.spage1493en_HK
dc.identifier.epage1496en_HK
dc.identifier.isiWOS:000169812000033-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridNgai, SW=7006074214en_HK
dc.identifier.scopusauthoridChan, YM=7403676661en_HK
dc.identifier.scopusauthoridTang, OS=7006723402en_HK
dc.identifier.scopusauthoridHo, PC=7402211440en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats